Becton, Dickinson and Company (NYSE:BDX) Issues Earnings Results, Beats Estimates By $0.04 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04, RTT News reports. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.42 EPS. Becton, Dickinson and Company updated its FY 2025 guidance to 14.250-14.600 EPS and its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $11.73 during trading on Thursday, hitting $228.33. The stock had a trading volume of 1,884,300 shares, compared to its average volume of 1,381,605. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The firm has a market cap of $66.00 billion, a P/E ratio of 49.40, a PEG ratio of 1.76 and a beta of 0.43. The business has a fifty day moving average of $237.53 and a two-hundred day moving average of $235.16. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $257.58.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.82%. Becton, Dickinson and Company’s dividend payout ratio is 78.19%.

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent research reports. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.